RESUMO
Paciente diagnosticada de colitis ulcerosa y artritis reumatoide que está siendo tratada con mesalazina e hidroxicloroquina y que presenta síntomas catarrales similares a los de la COVID-19. El seguimiento farmacoterapéutico (SFT) realizado a la paciente permite asociar estos síntomas con un efecto secundario debido a los medicamentos que toma, consistente en discrasias sanguíneas. La intervención, realizada con el propio estado de situación, para informar al médico, consigue que éste realice modificaciones del tratamiento hasta conseguir el control de la enfermedad mediante disminución de las dosis de los medicamentos utilizados. (AU)
Assuntos
Humanos , Agranulocitose , Coronavírus Relacionado à Síndrome Respiratória Aguda Grave , Preparações Farmacêuticas , Colite Ulcerativa , PacientesRESUMO
Ceftazidime is an antibiotic belonging to the group of third generation cephalosporins, frequently used in clinical practice for its broad antibacterial spectrum. A case report is presented on a 78-year-old man who entered the intensive care unit due to respiratory failure secondary to nosocomial pneumonia in the postoperative period of a laparoscopic hepatic bisegmentectomy for a hepatocarcinoma. It required invasive mechanical ventilation and was treated with ceftazidime, developing a progressive decrease in platelet count after the onset of this drug and after re-exposure to it, not coinciding with the introduction of other drugs. The adverse reaction was reported to the Spanish pharmacosurveillance system and according to the Naranjo algorithm the causal relationship was probable. Since no case of ceftazidime-induced thrombocytopenia was found in the literature, we consider knowledge of it relevant as an adverse effect to be taken into account given its potential severity, especially when it cannot be explained by other causes.
